Pharmacokinetic study of a combination chemo-endocrine treatment of paclitaxel and toremifene

被引：0
|
作者：
Saeki, T.
Okita, A.
Aogi, K.
Kakishita, T.
Okita, R.
Taira, N.
Takashima, S.
Fujita, K.
Nishikawa, K.
机构：
[1] Saitama Med Sch, Saitama, Japan
[2] Shikoku Canc Ctr, Matsuyama, Ehime, Japan
[3] Saitama Med Sch, Moroyama, Saitama, Japan
[4] Nippon Kayaku Co Ltd, Tokyo, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
13017
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Combined chemo-endocrine adjuvant therapy for patients with operable breast cancer: still a question
    Colleoni, M
    Coates, A
    Pagani, O
    Goldhirsch, A
    CANCER TREATMENT REVIEWS, 1998, 24 (01) : 15 - 26
  • [22] Successful chemo-endocrine therapy for multiple bone metastases and myelophthisis caused by occult breast carcinoma
    Kanno M.
    Nakamura S.
    Uotani C.
    Yamanaka S.
    Terasaki Y.
    Taniya T.
    Yonezawa T.
    Yonezawa K.
    Watanabe K.
    International Journal of Clinical Oncology, 2000, 5 (6) : 399 - 404
  • [23] (18)F flurothymidine (FLT) for imaging of tumor cell proliferation; an in vitro-study for monitoring chemo-endocrine treatment in breast cancer cells.
    Fersis, N
    Jusufoska, A
    Gargya, B
    Rupp, C
    Wallwiener, D
    Dittmann, H
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S285 - S286
  • [24] Bevacizumab combined with chemo-endocrine preoperative therapy in locally advanced operable breast cancers.
    Ferrari, B.
    Scarano, E.
    Pietri, E.
    Dellapasqua, S.
    Colleom, M.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S187 - S187
  • [25] Neoadjuvant Chemo-Endocrine Therapy for Hormone Receptor Positive Breast Cancer: A Meta-Analysis
    Li, Zhen-Yu
    Dong, Ying-Li
    Cao, Xiao-Zhong
    Ren, Sha-Sha
    Zhang, Zhen
    Matsubara, Shigeki
    CLINICAL AND EXPERIMENTAL OBSTETRICS & GYNECOLOGY, 2023, 50 (04):
  • [26] A clinical and pharmacokinetic study of the combination of carboplatin and paclitaxel for epithelial ovarian cancer
    N Siddiqui
    AV Boddy
    HD Thomas
    NP Bailey
    L Robson
    MJ Lind
    AH Calvert
    British Journal of Cancer, 1997, 75 : 287 - 294
  • [27] A clinical and pharmacokinetic study of the combination of carboplatin and paclitaxel for epithelial ovarian cancer
    Siddiqui, N
    Boddy, AV
    Thomas, HD
    Bailey, NP
    Robson, L
    Lind, MJ
    Calvert, AH
    BRITISH JOURNAL OF CANCER, 1997, 75 (02) : 287 - 294
  • [28] Principal factor analysis of predictive markers of response and resistance to primary chemo-endocrine treatment in elderly breast cancer (BC) patients.
    Generali, D. G.
    Fox, S.
    Buffa, F. M.
    Berruti, A.
    Brizzi, M.
    Allevi, G.
    Bonardi, S.
    Dogliotti, L.
    Bottini, A.
    Harris, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 32S - 32S
  • [29] Role of hypoxia-inducible factor 1 in predicting treatment efficacy in primary chemo-endocrine therapy in human breast cancer.
    Fox, SB
    Bottini, A
    Generali, D
    Bonardi, S
    Wigfield, S
    Brizzi, MP
    Campo, L
    Milani, M
    Allevi, G
    Berruti, A
    Dogliotti, L
    Harris, AL
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S49 - S49
  • [30] Pharmacokinetic evaluation of toremifene and its clinical implications for the treatment of osteoporosis
    Gennari, Luigi
    Merlotti, Daniela
    Stolakis, Konstantinos
    Nuti, Ranuccio
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2012, 8 (04) : 505 - 513
12345